**BREAKING: Prelude Therapeutics Reports Wider-Than-Expected Loss**
Prelude Therapeutics Inc (PRLD) reported FY 2025 net loss of $1.29 per share, wider than the -$0.18 loss estimated. Revenue was $12.1M. The clinical-stage precision oncology company focuses on developing novel cancer medicines for underserved patients, including SMARCA2 protein degraders and CDK9 inhibitors.
The company is advancing its pipeline of targeted therapies for advanced and metastatic solid tumors. The company’s lead programs include PRT3789 and PRT7732, both selective degraders targeting SMARCA2, as well as PRT2527 for advanced solid tumors.
A detailed analysis of Prelude Therapeutics Inc’s quarter follows shortly on AlphaStreet.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.